免疫疗法：替沙格赛定 - 首个获批的嵌合抗原受体T细胞疗法：对支付方和政策制定者的影响 - Suppr

Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.

作者信息

Prasad Vinay

机构信息

Division of Hematology and Medical Oncology, Knight Cancer Institute; Department of Preventive Medicine and Public Health; and Center for Health Care Ethics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA.

出版信息

Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4.

DOI:10.1038/nrclinonc.2017.156

PMID:28975930

Abstract

摘要

相似文献

Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.

Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4.

CAR T-cell therapy: perceived need versus actual evidence.

Lancet Oncol. 2018 Oct;19(10):1259. doi: 10.1016/S1470-2045(18)30698-3. Epub 2018 Oct 1.

[Chimeric antigen receptor T-cell therapy for hematological malignancies].

Rinsho Ketsueki. 2019;60(9):1351-1357. doi: 10.11406/rinketsu.60.1351.

Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.

Clin Pharmacol Ther. 2019 Jan;105(1):71-78. doi: 10.1002/cpt.1280.

Next Steps in the CAR Journey of a Thousand Miles.

Mol Ther. 2017 Oct 4;25(10):2226-2227. doi: 10.1016/j.ymthe.2017.09.013. Epub 2017 Sep 20.

Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.

Hum Gene Ther. 2018 May;29(5):534-546. doi: 10.1089/hum.2017.243. Epub 2018 Mar 14.

Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel.

Am J Kidney Dis. 2021 Jun;77(6):990-992. doi: 10.1053/j.ajkd.2020.08.017. Epub 2020 Oct 22.

Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.

Semin Oncol Nurs. 2019 Oct;35(5):150930. doi: 10.1016/j.soncn.2019.08.009. Epub 2019 Sep 25.

Safer CAR T-Cell Therapy.

JAMA. 2019 Jun 11;321(22):2155. doi: 10.1001/jama.2019.7551.

Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.

Br J Haematol. 2020 Sep;190(6):851-853. doi: 10.1111/bjh.16685. Epub 2020 May 1.

引用本文的文献

A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy.

Hum Vaccin Immunother. 2025 Dec;21(1):2518634. doi: 10.1080/21645515.2025.2518634. Epub 2025 Jun 17.

The design of retroviral vectors used in the CAR-T products, risk management, and future perspective.

MedComm (2020). 2025 Jan 24;6(2):e70067. doi: 10.1002/mco2.70067. eCollection 2025 Feb.

iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment.

Bioengineering (Basel). 2025 Jan 13;12(1):60. doi: 10.3390/bioengineering12010060.

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system.

J Hematol Oncol. 2024 Dec 18;17(1):122. doi: 10.1186/s13045-024-01648-0.

Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.

Theranostics. 2024 Sep 3;14(14):5528-5550. doi: 10.7150/thno.93745. eCollection 2024.

Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies.

Immunotargets Ther. 2024 Aug 27;13:413-433. doi: 10.2147/ITT.S474659. eCollection 2024.

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.

Signal Transduct Target Ther. 2024 Jul 1;9(1):166. doi: 10.1038/s41392-024-01852-x.

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.

J Cell Immunol. 2024;6(1):22-50. doi: 10.33696/immunology.6.189.

Cancer biotherapy: review and prospect.

Clin Exp Med. 2024 May 27;24(1):114. doi: 10.1007/s10238-024-01376-2.

Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.

Adv Drug Deliv Rev. 2024 Jun;209:115315. doi: 10.1016/j.addr.2024.115315. Epub 2024 Apr 25.

本文引用的文献

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.

JAMA Intern Med. 2017 Nov 1;177(11):1569-1575. doi: 10.1001/jamainternmed.2017.3601.

Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database.

Bone Marrow Transplant. 2013 Feb;48(2):294-300. doi: 10.1038/bmt.2012.133. Epub 2012 Jul 9.

Is patient travel distance associated with survival on phase II clinical trials in oncology?

J Natl Cancer Inst. 2003 Sep 17;95(18):1370-5. doi: 10.1093/jnci/djg035.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.

作者信息

Prasad Vinay

机构信息

出版信息

Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4.

DOI:10.1038/nrclinonc.2017.156

PMID:28975930

Abstract

摘要

相似文献

Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.

Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4.

CAR T-cell therapy: perceived need versus actual evidence.

Lancet Oncol. 2018 Oct;19(10):1259. doi: 10.1016/S1470-2045(18)30698-3. Epub 2018 Oct 1.

[Chimeric antigen receptor T-cell therapy for hematological malignancies].

Rinsho Ketsueki. 2019;60(9):1351-1357. doi: 10.11406/rinketsu.60.1351.

Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.

Clin Pharmacol Ther. 2019 Jan;105(1):71-78. doi: 10.1002/cpt.1280.

Next Steps in the CAR Journey of a Thousand Miles.

Mol Ther. 2017 Oct 4;25(10):2226-2227. doi: 10.1016/j.ymthe.2017.09.013. Epub 2017 Sep 20.

Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.

Hum Gene Ther. 2018 May;29(5):534-546. doi: 10.1089/hum.2017.243. Epub 2018 Mar 14.

Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel.

Am J Kidney Dis. 2021 Jun;77(6):990-992. doi: 10.1053/j.ajkd.2020.08.017. Epub 2020 Oct 22.

Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.

Semin Oncol Nurs. 2019 Oct;35(5):150930. doi: 10.1016/j.soncn.2019.08.009. Epub 2019 Sep 25.

Safer CAR T-Cell Therapy.

JAMA. 2019 Jun 11;321(22):2155. doi: 10.1001/jama.2019.7551.

Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.

Br J Haematol. 2020 Sep;190(6):851-853. doi: 10.1111/bjh.16685. Epub 2020 May 1.

引用本文的文献

A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy.

Hum Vaccin Immunother. 2025 Dec;21(1):2518634. doi: 10.1080/21645515.2025.2518634. Epub 2025 Jun 17.

The design of retroviral vectors used in the CAR-T products, risk management, and future perspective.

MedComm (2020). 2025 Jan 24;6(2):e70067. doi: 10.1002/mco2.70067. eCollection 2025 Feb.

iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment.

Bioengineering (Basel). 2025 Jan 13;12(1):60. doi: 10.3390/bioengineering12010060.

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system.

J Hematol Oncol. 2024 Dec 18;17(1):122. doi: 10.1186/s13045-024-01648-0.

Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.

Theranostics. 2024 Sep 3;14(14):5528-5550. doi: 10.7150/thno.93745. eCollection 2024.

Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies.

Immunotargets Ther. 2024 Aug 27;13:413-433. doi: 10.2147/ITT.S474659. eCollection 2024.

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.

Signal Transduct Target Ther. 2024 Jul 1;9(1):166. doi: 10.1038/s41392-024-01852-x.

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.

J Cell Immunol. 2024;6(1):22-50. doi: 10.33696/immunology.6.189.

Cancer biotherapy: review and prospect.

Clin Exp Med. 2024 May 27;24(1):114. doi: 10.1007/s10238-024-01376-2.

Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.

Adv Drug Deliv Rev. 2024 Jun;209:115315. doi: 10.1016/j.addr.2024.115315. Epub 2024 Apr 25.

本文引用的文献

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.

JAMA Intern Med. 2017 Nov 1;177(11):1569-1575. doi: 10.1001/jamainternmed.2017.3601.

Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database.

Bone Marrow Transplant. 2013 Feb;48(2):294-300. doi: 10.1038/bmt.2012.133. Epub 2012 Jul 9.

Is patient travel distance associated with survival on phase II clinical trials in oncology?

J Natl Cancer Inst. 2003 Sep 17;95(18):1370-5. doi: 10.1093/jnci/djg035.

Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献